Fig. 6
Combined MEK inhibition and agonist immunotherapy leads to enhanced efficacy of treatment against established TNBCs. Mice (n = 6 per group) bearing established AT3ova a, b, e, f or 4T1Ch9 c, d, g, h tumors were treated with vehicle or trametinib via daily oral gavage for 20 days (AT3ova) or 15 days (4T1Ch9) and either 2A3 isotype control, α-4-1BB, or α-OX-40 antibody alone; three doses (4T1Ch9) or four doses (AT3ova) via IP injection on days 0, 4, 8, and 12 or combination of trametinib and agonists. a–d Tumor growth volume (mm3) and e–h survival (n = 12) were monitored. End point was determined as when tumors reached an ethical limit of 1400 mm3. Experiments are a representative of n = 2–3 replicates, with pooled mouse numbers for survival (mean tumor volume ± SEM). Controls groups are duplicated between panels as these experiments were performed concurrently. P-values represent two-way ANOVA, post hoc Tuckey’s tests for tumor growth, and log ranked (Mantel–Cox) test for survival proportions. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
